DRMAW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW
Should you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.
Dermata Therapeutics vs.
Dermata Therapeutics (NASDAQ:DRMAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.
Dermata Therapeutics and 180 Life Sciences both received 0 outperform votes by MarketBeat users.
In the previous week, Dermata Therapeutics and Dermata Therapeutics both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 1.89 beat Dermata Therapeutics' score of 1.87 indicating that 180 Life Sciences is being referred to more favorably in the news media.
Summary
180 Life Sciences beats Dermata Therapeutics on 1 of the 1 factors compared between the two stocks.
Get Dermata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DRMAW vs. The Competition
Dermata Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DRMAW) was last updated on 1/30/2025 by MarketBeat.com Staff
